David H. Deaton, M.D., F.A.C.S.

Vascular Surgeon located in Takoma Park, MD & Frederick, MD

About Dr. Deaton

Dr. Deaton completed his surgical residency and research fellowship at the Hospital of the University of Pennsylvania ('92) and his vascular fellowship at UCLA ('94). Dr. Deaton has practiced in a variety of private and academic settings most recently as Chief - Division of Vascular and Endovascular Surgery at MedStar Georgetown University Hospital in Washington, DC, and also as Director, Clinical Vascular Research and Founder and Medical Director, Vascular Non-Invasive Laboratory. Dr. Deaton left Georgetown in 2013 to devote the majority of his time to medical device innovation and development. Since 2013 he has served as Chief Medical Officer for Endologix, Chief Medical Officer for Syntactx in addition to consulting for start-ups and established medical device companies. Since leaving full-time clinical practice he has practiced on a part-time basis at the Cleveland Clinic(Main Campus, Cleveland, OH) and the University of South Carolina/Palmetto Richland(Columbia, SC).

Dr. Deaton has been involved in the development and evolution of endovascular aortic therapy since its inception and contributed significantly to a variety of other interventional/endovascular techniques since 1993. He was a leading investigator in the first US EVAR (EVT/Ancure bifurcated endograft) trial and provided the primary FDA panel testimony for the first approved EVAR device in the United States in 1999. Dr. Deaton served as a primary investigator in Phase I clinical trials of four different aortic endograft technologies. He devoted 10 years to the development of the first endovascular suturing device (Aptus end anchor) to include pre-clinical development, first-in-man(Venezuela), and the first-in-man US and served as a primary clinical consultant to Aptus during that period. He has held academic appointments at UCLA, the University of Pennsylvania, East Carolina University, and the University of Maryland in addition to his tenure at Georgetown. Dr. Deaton has held leadership positions in several vascular societies, most recently as Chairman of the Political Action Committee of the SVS. His interest in new translational vascular therapies resulted in numerous roles at established and start-up medical device companies over the last 25 years. He has authored numerous peer and non-peer-reviewed articles as well as vascular text chapters throughout his career and has been a speaker and faculty member at more than 175 meetings in the US, EU, ANZ, and Asia.

Read more
,  Office of David  H. Deaton, M.D., F.A.C.S.

Dr. Deaton completed his surgical residency and research fellowship at the Hospital of the University of Pennsylvania ('92) and his vascular fellowship at UCLA ('94). Dr. Deaton has practiced in a variety of private and academic settings most recently as Chief - Division of Vascular and Endovascular Surgery at MedStar Georgetown University Hospital in Washington, DC, and also as Director, Clinical Vascular Research and Founder and Medical Director, Vascular Non-Invasive Laboratory. Dr. Deaton left Georgetown in 2013 to devote the majority of his time to medical device innovation and development. Since 2013 he has served as Chief Medical Officer for Endologix, Chief Medical Officer for Syntactx in addition to consulting for start-ups and established medical device companies. Since leaving full-time clinical practice he has practiced on a part-time basis at the Cleveland Clinic(Main Campus, Cleveland, OH) and the University of South Carolina/Palmetto Richland(Columbia, SC).

Dr. Deaton has been involved in the development and evolution of endovascular aortic therapy since its inception and contributed significantly to a variety of other interventional/endovascular techniques since 1993. He was a leading investigator in the first US EVAR (EVT/Ancure bifurcated endograft) trial and provided the primary FDA panel testimony for the first approved EVAR device in the United States in 1999. Dr. Deaton served as a primary investigator in Phase I clinical trials of four different aortic endograft technologies. He devoted 10 years to the development of the first endovascular suturing device (Aptus end anchor) to include pre-clinical development, first-in-man(Venezuela), and the first-in-man US and served as a primary clinical consultant to Aptus during that period. He has held academic appointments at UCLA, the University of Pennsylvania, East Carolina University, and the University of Maryland in addition to his tenure at Georgetown. Dr. Deaton has held leadership positions in several vascular societies, most recently as Chairman of the Political Action Committee of the SVS. His interest in new translational vascular therapies resulted in numerous roles at established and start-up medical device companies over the last 25 years. He has authored numerous peer and non-peer-reviewed articles as well as vascular text chapters throughout his career and has been a speaker and faculty member at more than 175 meetings in the US, EU, ANZ, and Asia.


Read less

Insurance

If you don't see your insurance here, please call us at 301-304-4616 to inquire further. We offer flexible payment options as well.

AETNA Better Health
Aetna Health Plans
Amerigroup
AmeriHealth Caritas District of Columbia
Anthem Blue Cross
Anthem Healthkeeper
Care First BCBS
CHAMP VA
Cigna Health Spring
Cigna Healthcare
Humana
Humana Tricare
John Hopkins Health Care
Johns Hopkins EHP
Johns Hopkins Healthcare Priority Partners
Johns Hopkins Medicare Advantage

Connect with us on Facebook!